Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

[1]  D. Goodsell.  PD-1 (Programmed Cell Death Protein 1) , 2016 .

[2]  L. Zitvogel,et al.  Trial Watch—Oncolytic viruses and cancer therapy , 2016, Oncoimmunology.

[3]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[4]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[5]  J. Wolchok,et al.  Cancer: Antitumour immunity gets a boost , 2014, Nature.

[6]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[7]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[8]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[9]  J. Wolchok,et al.  Immune modulation for cancer therapy , 2014, British Journal of Cancer.

[10]  H. Kohrt,et al.  Targeting CD137 enhances the efficacy of cetuximab. , 2014, The Journal of clinical investigation.

[11]  N. Segal,et al.  Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. , 2014 .

[12]  M. Dolled-Filhart,et al.  A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. , 2014 .

[13]  S. Gettinger,et al.  First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. , 2014 .

[14]  R. Motzer,et al.  Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. , 2014 .

[15]  E. Plimack,et al.  Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). , 2014 .

[16]  J. Taube,et al.  Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. , 2014 .

[17]  L. Weiner,et al.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. , 2014, Blood.

[18]  H. Kohrt,et al.  Intratumoral Immunization: A New Paradigm for Cancer Therapy , 2014, Clinical Cancer Research.

[19]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[20]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[21]  J. Waisman,et al.  HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers , 2014, Cancer Immunology, Immunotherapy.

[22]  J. Lunceford,et al.  Abstract A20: MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity. , 2014 .

[23]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[24]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[25]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[26]  Antonio Mori,et al.  Next generation sequencing: new tools in immunology and hematology , 2013, Blood research.

[27]  R. Emerson,et al.  High‐throughput sequencing of T‐cell receptors reveals a homogeneous repertoire of tumour‐infiltrating lymphocytes in ovarian cancer , 2013, The Journal of pathology.

[28]  Charles Swanton,et al.  Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas , 2013, The Journal of pathology.

[29]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[30]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[31]  D. Chen,et al.  Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients , 2013, Journal of Translational Medicine.

[32]  H. Robins.  Immunosequencing: applications of immune repertoire deep sequencing. , 2013, Current opinion in immunology.

[33]  B. Levine,et al.  Innovation and opportunity for chimeric antigen receptor targeted T cells. , 2013, Cytotherapy.

[34]  F. Marincola,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[35]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[36]  J. Riley.  Combination checkpoint blockade--taking melanoma immunotherapy to the next level. , 2013, The New England journal of medicine.

[37]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[38]  L. Zitvogel,et al.  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists , 2013, Cell Death and Differentiation.

[39]  N. Senzer,et al.  OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  L. Zitvogel,et al.  Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Bin Zhang,et al.  Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition , 2013, Clinical Cancer Research.

[42]  B. Prakken,et al.  Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. , 2013, Methods.

[43]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[44]  F. Marincola,et al.  The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment , 2013, Journal of Translational Medicine.

[45]  R. Ferris,et al.  Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients , 2013, Clinical Cancer Research.

[46]  S. Demaria,et al.  Combining radiotherapy and cancer immunotherapy: a paradigm shift. , 2013, Journal of the National Cancer Institute.

[47]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[48]  L. Galluzzi,et al.  Immunosurveillance against cancer-associated hyperploidy , 2012, Oncotarget.

[49]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[50]  N. Kawashima,et al.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. , 2012, The Journal of clinical investigation.

[51]  L. Zitvogel,et al.  Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death , 2012, Science Translational Medicine.

[52]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[53]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[54]  L. Zitvogel,et al.  Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens , 2012, Autophagy.

[55]  J. Wolchok,et al.  Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg). , 2012 .

[56]  J. Pers,et al.  Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy , 2012, Annals of Hematology.

[57]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[58]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[59]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[60]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[61]  R. Nussenblatt,et al.  Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[62]  C. Granqvist,et al.  Spectroscopic study of the photofixation of SO2 on anatase TiO2 thin films and their oleophobic properties. , 2012, ACS applied materials & interfaces.

[63]  R. Tibshirani,et al.  In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. , 2012, Blood.

[64]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[65]  Zhigang Tian,et al.  Defining the critical hurdles in cancer immunotherapy , 2011, Journal of Translational Medicine.

[66]  Sylvia Janetzki,et al.  Harmonization of Immune Biomarker Assays for Clinical Studies , 2011, Science Translational Medicine.

[67]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[68]  M. Kalos.  Biomarkers in T cell therapy clinical trials , 2011, Journal of Translational Medicine.

[69]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[70]  G. Dranoff,et al.  Cancer immunology—analysis of host and tumor factors for personalized medicine , 2011, Nature Reviews Clinical Oncology.

[71]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[72]  M. Ando,et al.  FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  Yan Zheng,et al.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. , 2011, Current opinion in immunology.

[74]  M. Disis,et al.  ELISpot for measuring human immune responses to vaccines , 2011, Expert review of vaccines.

[75]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[76]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Disis,et al.  TNM staging in colorectal cancer: T is for T cell and M is for memory. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[79]  H. Maecker,et al.  A Model for Harmonizing Flow Cytometry in Clinical Trials , 2022 .

[80]  R. Tibshirani,et al.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[82]  B. Lindgren,et al.  Allogeneic natural killer cells for refractory lymphoma , 2010, Cancer Immunology, Immunotherapy.

[83]  F. Marincola,et al.  Gene-expression profiling in vaccine therapy and immunotherapy for cancer , 2010, Expert review of vaccines.

[84]  S. Steinberg,et al.  Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[85]  M. Kalos.  An integrative paradigm to impart quality to correlative science , 2010, Journal of Translational Medicine.

[86]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[87]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[88]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[89]  J. Friedberg,et al.  Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. , 2009, Blood.

[90]  P. van Endert,et al.  Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.

[91]  M. Ychou,et al.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Wolchok,et al.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit , 2008, Proceedings of the National Academy of Sciences.

[93]  Nigel W. Hardy,et al.  Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project , 2008, Nature Biotechnology.

[94]  F. Marincola,et al.  The immunologic constant of rejection. , 2008, Trends in immunology.

[95]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  N. Aaronson,et al.  Treatment of vulvar intraepithelial neoplasia with topical imiquimod. , 2008, The New England journal of medicine.

[97]  M. Shlomchik,et al.  Antigen presentation and transfer between B cells and macrophages , 2007, European journal of immunology.

[98]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[99]  F. Hodi,et al.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[100]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[101]  Susan Holmes,et al.  Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer , 2005, PLoS medicine.

[102]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[103]  D. Ankerst,et al.  Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT , 2005, BMC Immunology.

[104]  H. Kohrt,et al.  Rapid Assessment of Recognition Efficiency and Functional Capacity of Antigen-Specific T-Cell Responses , 2005, Journal of immunotherapy.

[105]  C. N. Coleman,et al.  Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer , 2005, Clinical Cancer Research.

[106]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[107]  S. Holmes,et al.  Diversity and Recognition Efficiency of T Cell Responses to Cancer , 2004, PLoS medicine.

[108]  E. Kimby,et al.  Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Mario Roederer,et al.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[111]  R. Elashoff,et al.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[113]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[114]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[115]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[116]  R. Herberman,et al.  Adoptive Immunotherapy of Cancer , 1994, Clinical Immunotherapeutics.

[117]  P. Scardino,et al.  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. , 1991, The New England journal of medicine.

[118]  G. Trinchieri,et al.  Human natural killer cells. , 1979, Transplantation proceedings.

[119]  J. Glorioso,et al.  Engineering HSV-1 vectors for gene therapy. , 2014, Methods in molecular biology.

[120]  Sylvia Janetzki,et al.  Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. , 2012, Methods in molecular biology.

[121]  L. Downs,et al.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.

[122]  J. Dungan.  Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod , 2009 .

[123]  E. Kimby,et al.  Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  L. Zitvogel,et al.  Immune response against dying tumor cells. , 2004, Advances in immunology.

[125]  Crispen Rg.  BCG and cancer. , 1975, Canadian Medical Association journal.